Comparative Pharmacology
Head-to-head clinical analysis: IOPAMIDOL 370 versus MD 76R.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IOPAMIDOL 370 versus MD 76R.
IOPAMIDOL-370 vs MD-76R
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iopamidol is a nonionic, water-soluble, iodinated radiographic contrast agent that attenuates X-rays, thereby enhancing vascular and tissue contrast during imaging procedures. Its mechanism is physical rather than pharmacological, based on iodine content and osmolality.
MD-76R is a radiopaque contrast agent that contains iodine, which attenuates X-rays, thereby enhancing the contrast of blood vessels and tissues during radiographic procedures. It functions by increasing the absorption of X-rays in areas where it is present, allowing for visualization of vascular structures and organ perfusion.
1-2 mL/kg (370 mg iodine/mL) IV up to a maximum of 150 mL per procedure for contrast-enhanced CT; for angiography, dose varies by procedure.
2–4 mL/kg intravenously, maximum 150 mL per procedure.
None Documented
None Documented
Terminal elimination half-life is approximately 2 hours (range 1.5-2.5 hours) in patients with normal renal function. Prolonged to 10-70 hours in patients with renal impairment, necessitating dose adjustment or avoidance.
Terminal half-life 1-2 hours; prolonged in renal impairment.
Primarily renal; >90% of administered dose excreted unchanged in urine via glomerular filtration within 24-48 hours. Less than 1% excreted in feces or bile.
Primarily renal; 95% eliminated unchanged in urine within 24 hours; <1% fecal.
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent